Local aerosol foam

By using alkyl phosphate surfactants and liquefied hydrocarbon gas propellants in aerosol foams, the stability and ozone layer influence of low water-soluble pharmaceutical active agents in oil-in-water emulsion aerosol foams are solved, and stable Drug delivery and long-term storage performance.

CN119013001APending Publication Date: 2024-11-22ARCUTIS BIOTHERAPEUTICS INC

Patent Information

Application Number
CN202280092658.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-19
Filing Date
2022-12-23
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

It is difficult to effectively prepare stable aerosol foams, especially oil-in-water emulsion aerosol foams containing low water-soluble pharmaceutical active agents, resulting in low drug delivery efficiency and unstable product, and propellants have an impact on the ozone layer.

Method used

Using alkyl phosphate anionic surfactant or alkyl phosphate surfactant blends as emulsifiers, combined with propellants of liquefied hydrocarbon gases, such as propane/isobutane/butane blends, to form a stable aerosol Foam, ensuring that the drug does not degrade during long-term storage and has excellent aesthetics and physical properties.

Benefits of technology

The stable delivery of low-water-soluble drug active agents is achieved, ensuring the long-term stability and aesthetics of the foam, reducing the impact of propellants on the ozone layer, and improving the bioavailability of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013001A_ABST
    Figure CN119013001A_ABST
Patent Text Reader

Abstract

The present invention relates to an aerosol foam composition comprising an active pharmaceutical ingredient (API) having low water solubility, an emulsifier blend comprising cetostearyl alcohol, dicetyl phosphate and ceteareth-10 phosphate, and a hydrocarbon propellant. The aerosol foam composition is preferably an oil-in-water emulsion. The propellant is a mixture of liquefied hydrocarbon gases, preferably a propane / isobutane / butane blend. Aerosol foam generated by hydrocarbon propellants is stable, has consistent physical properties, excellent aesthetics, and does not produce recognizable API degradation under long-term or accelerated storage conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 294,178, filed on December 28, 2021, and U.S. Provisional Application Serial No. 63 / 371,967, filed on August 19, 2022. The contents of these applications are incorporated herein by reference in their entirety. Field of the Invention

[0003] The present invention relates to an oil-in-water emulsion aerosol foam composition having an alkyl phosphate anionic surfactant or an alkyl phosphate surfactant blend as an emulsifier. More specifically, the present invention relates to a pharmaceutically acceptable emulsion aerosol foam composition comprising a pharmaceutically active agent having low solubility in water and an emulsifier blend of cetearyl alcohol, dicetyl phosphate and ceteareth-10 phosphate (also known as ceteth-10 phosphate). The aerosol foam is dispensed using a propellant blend. Background Art

[0004] Foam formulations have been used as delivery systems for cosmetic and pharmaceutical applications for decades. In some applications, foams are preferred because foams are easier to spread and minimize rubbing. This is particularly advantageous when treating irritated skin or skin areas covered with hair. Foam carriers are more preferred than ointments, gels and creams because they are easy to apply, have reduced viscosity and reduced greasiness. Patient preference for foam carriers can lead to increased patient compliance and therefore better treatment results.

[0005] There are different types of foam formulations that can be used to deliver active ingredients, including aqueous, hydroalcoholic, emollient, solvent-based, petrolatum-based, and oil-based foams. Different formulations have different properties, for example, emollient foams have a soothing and moisturizing effect, and hydroalcoholic foams promote skin penetration and solubility of the active agent. Foams can be produced using propellant-free methods such as A foam dispenser (a foam dispenser having a pump assembly including a liquid pump, an air pump and a common priming component for activating both the liquid pump and the air pump) or by using a pressurized container and a propellant.

[0006] Topical foams differ from ointments and creams in that the characteristics of the foam carrier are changed. Prior to application, foam formulations are typically in the form of a suspension or emulsion. As aerosol foam formulations are expelled from the container, the liquid propellant evaporates, thereby producing a semisolid foam product that is expanded with a gaseous propellant. If a propellant-free generation method is used, air is simultaneously pumped into the suspension or emulsion as the foam is dispensed. The method used to generate the foam affects the foam appearance and stability.

[0007] Foams can be designed to have specific properties, depending on various factors such as the condition being treated, the area of ​​the body being treated, and the active pharmaceutical ingredient in the formulation. The foam carrier should have suitable stability so that it will not collapse after being discharged from the container; low shear sensitivity so that only minimal rubbing is required; it should be non-irritating, non-allergenic and non-toxic; and the active agent should be kept dissolved. In addition, the aerosol foam carrier should contain a propellant that has minimal or no effect on the atmospheric ozone layer. The foam applied to the face or upper torso should have minimal odor, because adding fragrances to mask malodors is not preferred for pharmaceutical products. The foam structure is affected by various parameters, including the type and concentration of the foaming agent, the viscosity of the liquid phase, the salt concentration, the temperature, and the pH value of the formulation.

[0008] Commercially available three-phase pharmaceutical aerosols rely on surfactants with limited solubility in both the internal oil phase and the external aqueous phase. After shaking, liquid hydrocarbon propellants are mixed with dispersed globules of the oil phase. Surfactants are concentrated at the interface between the propellant / oil phase and the aqueous phase to form a film called a "thin layer". Once the medicinal emulsion leaves the pressurized environment of the aerosol can, when the liquid propellant in the internal phase is converted into a gas, foam is formed at this time, and the structural strength and general characteristics of the foam are determined by the specific composition of the thin layer. This liquid phase to gas phase transition forms bubbles of the foam. Thick and tight lamellar thin layers can produce very tightly structured foams that can support their weight. Stable foams are not always formed. The formation of stable foams with desired structures depends on many factors, including but not limited to specific components, concentrations of components, viscosity of the liquid phase and propellants. These factors can be adjusted to produce stable foams with different structures, such as expanded foams, fast-breaking foams, hard foams and stout foams.

[0009] Foam collapse occurs when the pressure generated by the expansion of the internal gas phase exceeds the cohesive strength of the foam lamina. Three sources of internal gas phase expansion are: 1) additional degassing of the lower vapor pressure liquid hydrocarbon propellant, 2) mechanical pressure (push) exerted on the foam during rubbing, and 3) after adiabatic cooling (70 psig) of the foam concentrate as it passes this value and becomes a foam at ambient pressure, the foam is typically warmed to ambient temperature (20-25°C) or skin temperature (32°C). For three-phase emulsion pharmaceutical foams stabilized by alkyl phosphate surfactants, once the lamina is reduced to a single surfactant bilayer film, additional expansion of the internal gas phase will cause the cells of the foam to rupture and expel the product onto the skin surface.

[0010] Expanding and fast-breaking foams are characterized by the expanding internal gas phase that rapidly causes the thin layer to break to produce significantly larger foam cells. As the internal foam cells combine, the expanding foam will initially appear to "swell", but as the foam cells on the surface collapse, the expulsion of the product will deliver the active to the skin application site.

[0011] For hard and thick foams, the fully degassed internal phase warmed to skin temperature does not generate enough pressure to exceed the cohesive strength of the thin layer. The bubbles do not break until applied rubbing pressure occurs. These more stable foams are ideal for scalp application because the foam can be placed in a "part of the hair" against the scalp lesion and then rubbed to break the foam and apply the active agent to the affected skin while minimizing the loss of product to the hair.

[0012] In order to make the three-phase drug emulsion foam commercially acceptable, the liquid hydrocarbon propellant must be properly mixed with the internal oil phase of the emulsion so that the product forms a foam when it leaves the tank. If the propellant is not properly mixed, only a small amount of foam cells will be formed when the liquid propellant is converted into gas, and most of the propellant will be converted into gas outside the emulsion when it is started. When shaken and immediately started by the valve, uneven and very dense unacceptable "sputtering" foam will be distributed. Since the propellant will be distributed separately from the emulsion concentrate even if the tank is properly shaken and inverted, the propellant will be emptied from the tank before the entire amount of product is discharged. Since the tank is not completely emptied, this foam product is commercially unacceptable. For example, if the prescription product can deliver 60 grams of foam (a month's supply), but the propellant is completely exhausted after delivering 48 grams of foam, the patient will not be able to receive the complete prescribed treatment. Such a foam tank does not meet the minimum delivery quality requirements and will be recalled from the market.

[0013] Stable foam is not always formed. The formation of stable foam with the desired structure depends on many factors, including but not limited to the specific components, the concentration of the components, the viscosity of the liquid phase and the propellant. Any excipient added to the formulation and capable of increasing the solubility of the surfactant in the external aqueous phase can destabilize the emulsion, reduce the rigidity of the thin layer and cause the foam bubbles to burst when the liquid propellant is converted into a gas. In other words, the fluid emulsion will be dispensed from the tank and quickly flow away from the skin application site, rather than forming a localized foam that remains at the application site until the thin layer is destroyed by rubbing and the drug product is released to the desired treatment site.

[0014] It has been shown that the cosmetic and pharmaceutical solvent diethylene glycol monoethyl ether (DEGEE) remains in the aqueous continuous phase of the emulsion and increases the solubility of the surfactant and wax components of the thin layer in the continuous aqueous phase during the emulsification process (Hernandez et al., Journal of Dispersion Science and Technology, Investigating the effect of transcutol on the physical properties of an O / W cream, Vol. 41, No. 4, pp. 600-606, 2020). When the DEGEE concentration increases above 25%, the stability of polyoxyethylene-20-stearyl ether and polyoxyethylene-2-stearyl ether emulsions decreases sharply, indicating that it is surprising to maintain a sufficiently thick and tightly stratified thin layer to produce stable foam in the presence of 25% or more DEGEE.

[0015] Foam stability can be assessed by determining the foam half-life. The foam half-life is the time required to expel half of the volume of the liquid continuous phase of the foam product. The shorter the half-life, the lower the foam stability. The desired foam half-life will be based on the intended use of the foam. For certain foam applications (e.g., self-tanning foams and sunscreen foams) where the foam is applied to a large area of ​​the body surface, the foam half-life is preferably less than 30 seconds to minimize the application time. For the topical medicated foams of the present invention, the foam half-life is preferably greater than 30 seconds, and in some embodiments, the foam half-life is preferably greater than one minute.

[0016] Aerosol foams have been found to produce stable foams suitable for topical administration of active pharmaceutical ingredients (API). Aerosol foam formulations consist of two components: a product concentrate and a propellant. A product concentrate is a combination of an active drug and additional ingredients or cosolvents required to make a stable and effective product. The concentrate of a pharmaceutical aerosol formulation can be a solution, a suspension, an emulsion, a semisolid, or a powder. Topical foam products typically have an emulsion product concentrate. The propellant provides the force to discharge the product concentrate from the container and is also responsible for delivering the formulation in a foam form. The propellant can also be used as a solvent for the pharmaceutical active or as a functional excipient to supplement the product concentrate.

[0017] Unfortunately, it can be difficult to formulate a stable aerosol foam containing a low water soluble API. The low water soluble API may not be delivered continuously at a high enough concentration to produce the desired therapeutic effect under long-term or accelerated storage conditions, and / or the bioavailability may be reduced. In addition, undissolved API may clog the valve. This is more likely to occur when the low water soluble API is used in a formulation containing a large amount of water (such as an oil-in-water emulsion). A stable foam product containing a fully dissolved low water soluble API will improve efficacy and patient compliance.

[0018] Propellant

[0019] Propellants are used to create pressure within the container and expel the product concentrate from the container. Propellants are chemicals whose vapor pressure at 40°C (105°F) is greater than atmospheric pressure. Pharmaceutical aerosols are usually made using propellants such as chlorofluorocarbons, fluorocarbons (trichloromonofluoromethane, dichlorodifluoromethane), hydrocarbons (propane, butane, isobutane), hydrochlorofluorocarbons and hydrofluorocarbons, and compressed gases (nitrogen, NO2, CO2).

[0020] Chlorofluorocarbon (CFC) propellants have been used for many years, however, due to their role in depleting the ozone layer, the use of CFCs has decreased significantly.

[0021] Hydrochlorofluorocarbons (HCFCs) and hydrofluorocarbons (HFCs) differ from chlorofluorocarbons (CFCs) in that they may or may not contain chlorine and have one or more hydrogen atoms. HCFCs and HFCs have less impact on the ozone layer because their decomposition rate in the atmosphere is faster than CFCs. HCFCs and HFCs are used in topical medications. HCFCs and HFCs have greater miscibility with water, so they are more suitable for use as solvents than other propellants. For foam concentrates consisting of oil-in-water emulsions, HCFCs and HFCs are easily blended with the continuous phase of the emulsion and provide excellent topical drug delivery vehicles for highly water-soluble active substances (such as urea and salicylic acid). 42 Moisturizing Foam is a keratolytic moisturizing foam which is a tissue softener for skin and / or nails containing urea, preservatives, buffers, water, ceteareth-10 phosphate, cetearyl alcohol and dicetyl phosphate. The emollient foam is a keratolytic containing 6% salicylic acid (USP) incorporated into a water-based emollient foam carrier containing humectants, preservatives, buffers, water, ceteareth-10 phosphate, ceteth-20 phosphate, cetearyl alcohol, dicetyl phosphate and propylene glycol.

[0022] Hydrocarbon (HC) propellants are used for topical drug aerosols because they have less impact on the environment, low toxicity and no reactivity. HC can also be used to prepare three-phase (double-layer) aerosols because its density is less than 1 and it is immiscible with water. Hydrocarbons remain on the upper part of the water layer and provide the force to push the contents out of the container. Hydrocarbons do not contain halogens, so hydrolysis does not occur, making them good propellants for water-based aerosols. Unfortunately, hydrocarbon propellants are flammable and may explode. The flammability can be reduced by mixing hydrocarbons with other liquefied gases. The liquid hydrocarbon propellant in the tank may mix poorly with the internal oil phase of the water-in-oil emulsion and make the foam concentrate unstable. This results in uneven content of the dose sprayed from the tank. For this reason, water-in-oil emulsion aerosol foam products that do not deplete the ozone layer have not yet been developed containing water-insoluble APIs.

[0023] Table 1. Properties of hydrocarbon propellants

[0024]

[0025] Propane, butane, and isobutane are the most commonly used hydrocarbons. They are used alone or as a mixture to obtain the desired vapor pressure, density, and flammability. Blends of propane, isobutane, and n-butane are often referred to as "AP" or "NIP," followed by a dash and a value indicating the pressure (in pounds per square inch, as measured by a pressure gauge) of the specific propellant blend at 70°F. For example, AP-48 propellant is a blend of 31:23:46 propane:isobutane:butane with a tank pressure of 48 psig at 70°F, while AP-70 propellant is a blend of 55:15:30 propane:isobutane:butane with a tank pressure of 70 psig at 70°F.

[0026] Inert compressed gas propellants discharge the product concentrate in essentially the same form as when it was placed in the container. The pressure of the compressed gas is located in the head space of the aerosol container. Compressed gas propellants are easy to obtain, inexpensive and non-flammable, but as the product is used up, the pressure in the tank decreases. For pharmaceutical products, the steady drop in pressure at each activation may result in a significant difference between the first dose of active substance delivered from the tank and the last dose of active substance delivered. In addition, once the compressed gas is exhausted, any remaining product in the tank cannot be given to the patient. For these reasons, compressed gas propellants are not usually used for pharmaceutical aerosols.

[0027] Product Concentrate

[0028] Aerosol foam is produced when an oil-in-water emulsion product concentrate is mixed with a propellant and the propellant is in the internal oil phase of the emulsion. If the propellant is in the external phase (i.e., like a water-in-oil emulsion), no foam is produced, but a spray or wet stream is produced. Rapidly breaking foam produces foam when sprayed from a container, but the foam collapses in a relatively short time. This foam is used to apply the product concentrate to a large area without manually rubbing or spreading the product. Since the foam collapses quickly, the active drug can take effect faster. When a surfactant with limited solubility in both the organic phase and the aqueous phase is used, a stable foam is produced. The surfactant concentrates at the interface between the propellant / oil phase and the aqueous phase to form a film known as a "thin layer". It is the specific composition of the thin layer that determines the structural strength and general properties of the foam. Thick and tightly stacked thin layers produce a very dense foam that can support its own weight.

[0029] The emulsifier or surfactant used to formulate the product concentrate and the use of alcohols in the formulation are two of the most important components in topical pharmaceutical foams. Surfactants in emulsion aerosols can include fatty acids saponified with triethanolamine, anionic surfactants, and more recent nonionic surfactants such as polyoxyethylene fatty acid esters, polyoxyethylene sorbitan esters, alkylphenoxyethanols, and alkanolamides. The first dermal foams contained high levels of alcohols (about 60% ethanol) and used the nonionic surfactant polysorbate 60 and a hydrocarbon propellant to produce a fast-bursting foam. Topical Foams (clobetasol), (Betamethadone), (Halobetasol) and (Clindamycin) is a high alcohol foam. Unfortunately, high alcohol foams were found to sting and burn some psoriasis patients, so alcohol was removed from clobetasol foam and polysorbate 60 was replaced with polyoxyl 20cetostearyl ether to launch the first emollient topical medicated foam The composition of local foam is very similar to FDA in that the foam contains propylene glycol but no alcohol and uses a surfactant blend of polysorbate 80 and polyoxyethylene (40) stearate to form the foam sheet. The latest advance in topical pharmaceutical foam technology is the development of topical pharmaceutical foams for the treatment of acne and rosacea. Topical Minocycline Foam. This product contains no solvents, but instead uses a blend of natural oils to dissolve the minocycline, combined with hydrogenated castor oil as a surfactant to form a thin layer of foam. Summary of the invention

[0030] The present invention relates to an aerosol foam composition comprising an API having a water solubility of less than 60 mg / l. The aerosol foam composition is preferably an oil-in-water emulsion in combination with a propellant, the oil-in-water emulsion containing an emulsifier blend of cetearyl alcohol, dicetyl phosphate and ceteareth-10 phosphate. The propellant is a mixture of liquefied hydrocarbon gases, preferably a propane / isobutane / butane blend. The hydrocarbon propellant produces an aerosol foam containing a low water-soluble API that is stable, has consistent physical properties, excellent aesthetics, and does not show discernible degradation of the API after long-term (storage for more than 24 months at ambient temperature) or accelerated storage conditions (storage for 6 months at 40°C and 75% relative humidity). BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 A-1E shows acceptable and unacceptable foam. Figure 1 A-1D shows acceptable foam structures immediately after dispensing and 5 minutes after dispensing, including expanding foam, fast-breaking foam, rigid foam, and thick solid foam. Figure 1 E shows unacceptable foam due to inadequate mixing of the propellant and concentrate resulting in splashing during dispensing.

[0032] Figure 2 Acceptable foams containing ketoconazole according to Formulations 5-8 at 5 minutes after dispensing are shown. Formulations 5 and 7 produced acceptable expanded foams. Formulation 6 produced an acceptable thick solid foam. Formulation 8 produced an acceptable hard foam.

[0033] Figure 3 Acceptable and unacceptable foams containing econazole nitrate according to Formulations 9-12 at 5 minutes after dispensing are shown. Formulation 9 produced unacceptable splattering foam. Formulations 10 and 12 produced acceptable thick solid foams. Formulation 11 produced unacceptable splattering foam.

[0034] Figure 4Acceptable foams containing ivermectin according to Formulations 13-16 are shown at 5 minutes after dispensing. Formulations 13-15 produced acceptable expanding foams and Formulation 16 produced acceptable fast-bursting foams.

[0035] Figure 5 Acceptable fast-bursting foams containing clobetasol propionate according to formulations 17-20 are shown at 5 minutes after dispensing.

[0036] Figure 6 Acceptable and unacceptable foams containing oxymetazoline according to Formulations 21-24 at 5 minutes after dispensing are shown. Formulation 21 produced an acceptable thick, solid foam. Formulation 22 produced an unacceptable, splattering foam. Formulations 23 and 24 produced acceptable, hard foams. DETAILED DESCRIPTION

[0037] It has been found that topical administration of effective agents to treat skin diseases provides patients with excellent delivery, lower systemic exposure and greater ease of use. The molecular structure of the compound ultimately determines the ability of the drug to pass through the epithelium of the tissue to which the product is applied. For skin application, the selection of formulation components determines the maximum skin penetration that the formulator can achieve. The present invention is applicable to many APIs, particularly low water-soluble APIs. Examples of low water-soluble APIs suitable for the present invention include, but are not limited to, ketoconazole, econazole nitrate, ivermectin, clobetasol propionate, calcipotriene, halobetasol propionate, tazarotene, oxymetazoline free base and desonide. Low water-soluble APIs are defined herein as APIs with a water solubility of 60 mg / l or less. Creams, lotions, gels, ointments, aerosol foams, and solutions are just some of the more common forms of topical formulations for application to the skin that typically contain fully dissolved APIs, as disclosed in U.S. Pat. No. 5,712,298 (the "'298 patent") for roflumilast, which is incorporated herein by reference (column 12, lines 37-64). For the treatment of such skin diseases, emulsions, suspensions, gels, or solutions for topical application have been described, although the low solubility of the compound has limited these applications.

[0038] A cream formulation containing a low water-soluble API is combined with a propellant. The foam concentrate is formulated to produce a foam that does not collapse after being discharged from the container; has low shear sensitivity, so only minimal rubbing is required; is non-irritating, non-allergenic and non-toxic; and keeps the API dissolved. In addition, the aerosol foam carrier contains a propellant that has minimal or no effect on the ozone layer of the atmosphere. The components in the foam concentrate and the propellant can be adjusted to produce foams with different properties, such as expanding foam, fast-breaking foam, hard foam and thick solid foam. Preferably, the product squeezed out of the can is a smooth white or off-white foam with uniform bubbles that can support its own weight until rubbing begins. Once rubbing begins, the foam will break quickly to spread evenly on the application site. The foam half-life of the product is preferably greater than 60 seconds. The amount of foam dispensed by the can can be metered or unmetered to dispense a consistent amount of foam and a consistent dose of API.

[0039] The aerosol foam comprises 1-10%, preferably 2-5%, of an emulsifier containing an alkyl phosphate anionic surfactant or a blend of alkyl phosphate surfactants to ensure mixing with the propellant. The emollient or oil content should be able to produce an aesthetically pleasing foam. Preferably, the emollient comprises 2-6%, preferably 5% petrolatum; and 2-3%, preferably 2.5% isopropyl palmitate. Preferably, the oil comprises 8-12% diisopropyl adipate and 8-12% oleyl alcohol.

[0040] The propellant provides the force to expel the product concentrate from the container and is also responsible for delivering the formulation in the form of a foam. Since aerosol foam propellants are mixtures of liquefied hydrocarbon gases, they can also be used as solvents for the API or can be mixed with the internal oil phase of the product concentrate emulsion. The use of hydrocarbon propellants can reduce or eliminate the need for additional solvents such as hexylene glycol and DEGEE (diethylene glycol monoethyl ether). The amount of hexylene glycol is preferably 0-20% w / w, and the amount of DEGEE is preferably 10-35% w / w. The hydrocarbon propellant partially mixes with the API concentrate, but mainly forms a separate liquid layer (less dense than the concentrate) within the can. This is generally referred to as a three-phase drug aerosol. Therefore, before the sprayed foam is applied to the patient's skin, the can must be shaken to evenly distribute the propellant throughout the finished product.

[0041] Product Concentrate

[0042] The product concentrate in the foam consists of low water soluble active substance, 10-35% of diethylene glycol monoethyl ether NF 30-80% water, 7.5-20% oil phase and 1-10% (in some embodiments 2-5%) anionic surfactant based emulsifying wax Crodafos CES TMCrodafos CES 1000 is a foam concentrate which is a combination of an aqueous emulsion of 1,200 ml of water and an oil-in-water emulsion. These components produce a foam for treating the scalp and face. This foam concentrate can form a fast-breaking, expanding foam that breaks within a relatively short time after application to the skin (without rubbing). This type of foam is used to apply the product concentrate to large areas without manually rubbing or spreading the product. The active drug can be obtained more quickly because the foam collapses quickly and the foam is more easily applied to skin areas with a high density of terminal hair, i.e. the scalp. Depending on the amount of low water-soluble active substance selected and the oil phase and / or emulsifying wax, this foam concentrate can also form a stable foam that does not break until the product sprayed from the can is rubbed. Table 3 gives a series of Crodafos CES 1000. TM Viscosity values ​​for concentrations. 10% Crodafos CES containing 0.3% roflumilast as a low water soluble active substance TM Unacceptable foam is produced which can "sputter" when sprayed from the can. Sputtering (e.g. Figure 1 E) indicates that the mixing between the liquid propellant and the emulsion foam concentrate in the can is not sufficient. However, the 2% Crodafos CES containing 0.3% roflumilast TM The formulation produced an acceptable hard foam (e.g. Figure 1 C).

[0043] The final composition of the 0.3% roflumilast foam is given in Table 2. Roflumilast spray foam products with this composition had consistent physical properties, excellent aesthetics, no discernible degradation of roflumilast after long-term (24 months or longer under ambient conditions) or accelerated storage conditions (6 months at 40°C and 75% relative humidity), and exhibited acceptable but variable roflumilast assay results during the study period. A series of quantitative tests were completed through designed experiments that focused on analytical methods for sample formulations, optimization of product concentrates, and characterization of packaging compatibility. It was determined that the variability in analytical results could be minimized by the addition of hexane extraction during sample preparation.

[0044] Table 2. Composition of ARQ-154 foam product

[0045]

[0046] *Add 8-10 grams of propellant to 64 grams (target) of emulsion concentrate to deliver a minimum of 60 grams of foam product

[0047] The preferred viscosity is 4000-11,000 centipoise (cP). The viscosity is tested using a Brookfield viscometer, which determines viscosity by measuring the force required to rotate a spindle in a sample at a given rate. A conventional viscosity spring (RV), a No. 14 spindle, a speed of 30 rpm, and a sample chamber of 6R are used. However, any digital viscometer (DVE, DV1, DV2, or DV3) is suitable for determining viscosity. The reading time is 2 minutes and the temperature is controlled room temperature (CRT, 20-25°C).

[0048] Table 3. 2% Crodafos CES for the 0.3% roflumilast formulations shown in Table 2 TM Viscosity values ​​for different CrodafosCES levels in formulations

[0049]

[0050] Sprayed foam products containing low water soluble actives have consistent physical properties, excellent aesthetics, acceptable assay results, and do not produce deleterious amounts of degradation products after long term (3 months or more storage at ambient conditions) or accelerated storage conditions (3 to 6 months storage at 40°C and 75% relative humidity). Table 4 (Long term storage stability) and Table 5 (Accelerated storage stability) give the 2% Crodafos CES stability of the 0.3% roflumilast formulations described in Table 2. TM Typical data generated for formulations with low water soluble actives. The preferred aesthetics of the foam concentrate were optimized by reducing the emollients by half (petrolatum 5% instead of 10%, isopropyl palmitate 2.5% instead of 5.0%). Only two 2% Crodafos CES were compared. TM Foam concentrate formulation to optimize the aesthetics of the foam formulation. The foam concentrate containing 15% combined moisturizer felt "greasy" during rubbing compared to the foaming concentrate containing 7.5% combined moisturizer. Since the foam product is formulated for the treatment of seborrheic dermatitis skin on the scalp and face, two anatomical sites where the skin is known to be greasy before the foam is applied, it is believed that reducing the moisturizer content of the foam compared to the cream has an aesthetic advantage. To compensate for the removal of the 15.5% emulsifier / emollient, the amount of water in the foam was increased to slightly over 65% in the foam concentrate, compared to about 50% water in the roflumilast cream. Three-month informal stability data for a 64-gram product concentrate formulation aerated with 8 grams of AP-70 propellant are shown in Tables 4 and 5 (Table 2).

[0051] Table 4. 0.3% Roflumilast Formulations in 2% Crodafos CES TM Stability data of the formulation stored inverted at 25°C

[0052] test T=0 T = 1 month T = 2 months T = 3 months describe* satisfy satisfy satisfy satisfy pH 5.44 5.26 5.29 5.29 Pressure@25℃ 58psi 75psi 65psi 73psi Delivery rate@25℃** 1.64g / sec 2.18g / sec 2.38g / sec 1.91g / sec Foam density 0.091g / mL 0.112g / mL 0.104g / mL 0.104g / mL ^Determination of roflumilast 99.0% 99.9% 97.0% 99.4% ^Determination of methyl paraben 99.7% 99.6% 100.2% 98.1% ^Determination of propylparaben 99.7% 99.3% 99.5% 98.4%

[0053] ^Assay % scalar Claimed results are the average of n=9 replicates per assay and time point and were normalized to the bulk formulation concentrate.

[0054] *Description: White opaque foam with dense small bubbles. The foam is not runny.

[0055] **(Average delivery rate, g / sec): Method: USP 603

[0056] Table 5. 0.3% Roflumilast Formulations in 2% Crodafos CES TM Stability data of the preparation stored inverted at 40°C

[0057]

[0058] NT = Not Tested

[0059] ^Assay % scalar Claimed results are the average of n=9 replicates per assay and time point and were normalized to the bulk formulation concentrate.

[0060] *Description: White opaque foam with dense small bubbles. The foam is not runny.

[0061] **(Average delivery rate, g / sec): Method: USP 603

[0062] Propellant

[0063] Hydrocarbon propellants have been found to produce topical foams with desirable properties. They do not contain halogens and therefore do not undergo hydrolysis, making these propellants well suited for use in water-based aerosols such as oil-in-water emulsions containing low water-soluble APIs.

[0064] 2% Crodafos CES with 0.3% roflumilast formulation as described in Table 2 TMFormulations Six different hydrocarbon propellants, one n-butane / dimethyl ether blend, and one hydrofluorocarbon propellant were screened. The six hydrocarbon propellants were isobutane (A-31), n-butane (A-17), propane / isobutane (A-46), propane / isobutane (A-70), propane / isobutane / n-butane (AP-70), Aeropin 35 (Aeropin 35 is a blend of propane / isobutane / n-butane with a vapor pressure of 35 psig at 70°F, so the ratio of isobutane to n-butane is fixed at 2 / 3), and Butane 48 (Butane 48 is a blend of propane / isobutane / n-butane / isopentane in a ratio of 30.8 / 22.9 / 45.8 / 0.5). The blend of hydrocarbons with dimethyl ether (DME) was 53% DME and 47% n-butane. The hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane (HFA 134a). In the initial foam propellant screening study, AP-70 propellant produced the best foam quality. It will be used for highly water-soluble urea and salicylic acid The propellant HFA-134a (1,1,1,2-tetrafluoroethane) in the emollient foam was combined with Formulation 1. The sprayed product was a clumpy, gel-like material without gas bubbles distributed in the liquid. Table 1 provides the properties of these three hydrocarbon propellants blended to produce the aerosol propellants designated as "AP" or "NIP", and Table 6 lists the appearance of the aerosolized topical foam products.

[0065] Table 6. 2% Crodafos CES containing 0.3% Roflumilast TM Foam appearance of formulations in combination with different commercially available propellants

[0066]

[0067]

[0068] The aesthetics of the foam formulations shown in Table 2 (64 grams of concentrate, 2% Crodafos CESTM formulation containing 0.3% roflumilast) aerated with 8 grams of AP-48 or AP-70 propellants were compared. The AP-48 propellant is a blend of propane:isobutane:butane of 31:23:46, while the AP-70 propellant is a blend of propane:isobutane:butane of 55:15:30. Although both foams were found to be completely acceptable, about two-thirds of the individuals who tested these products preferred the firmer appearance and slightly slower rupture of the AP-48 propellant foam. The other third of the testers had no preference or a slight preference for the faster rupture AP-70 foam. In conclusion, both AP-48 and AP-70 hydrocarbon blends exhibited good local foam properties and excellent aesthetics. By adjusting the ratio of propane to butane, any pressure between 48 and 70 psig can be achieved. It has been shown that hydrocarbon propellant blends of propane / isobutane / n-butane in any ratio producing pressures around 48-70 psig at 70°F are acceptable from an aesthetic point of view.

[0069] Foam products

[0070] Aerosol foam is produced when the oil-in-water emulsion product concentrate is mixed with a liquid hydrocarbon propellant and the propellant is in the internal oil phase. If the propellant is in the external phase (i.e., like a water-in-oil emulsion), no foam will be produced, but a spray or wet stream will be produced. When a surfactant with limited solubility in both the internal oil phase and the external water phase is used, a stable foam will be produced. The surfactant concentrates at the interface between the propellant / oil phase and the water phase to form a thin film called a "thin layer". It is the specific composition of the thin layer that determines the structural strength and general properties of the foam. Thick and tightly stacked thin layers produce a very densely structured foam that can support its own weight. In a preferred embodiment, two alkyl phosphate surfactants that are not commonly used in topical foam products are used. These alkyl phosphate surfactants are in the emulsifier Crodafos CES TM middle.

[0071] For all topical drug foams, it is assumed that when the last lamella breaks (the foam bubble breaks), all the propellant is released from the formulation. The specific composition of the foam lamella determines the structural strength and general properties of the foam. Liquid crystal stabilized oil-in-water emulsions The low water-soluble API concentrate has multiple Crodafos CES lamellae around each oil droplet. The solvent DEGEE (diethylene glycol monoethyl ether) is miscible with both water and oil, so it is likely to be distributed between the oil phase and the water phase and distributed in the multiple lamellae at the emulsion interface. The concentrate is added to the can, the valve is crimped in place on the top of the can and the propellant is added under pressure through the valve of the main container closure system. In the can, some liquid propellant will be distributed into the oil phase. When the can is shaken, the propellant easily mixes with the oil droplets of the concentrate to form a milky emulsion in the can. When the propellant is ejected from the can, it changes from liquid to gas under pressure, and the volume of the liquid propellant left in the oil ball will expand rapidly to become hydrocarbon bubbles trapped in the foam lamella. As the propellant expands, the multiple thin layers of droplets quickly become a single thin layer of foam. Once the pressure associated with the volume of the gas propellant exceeds the strength of the thin layer of surfactant, the foam cells rupture and the API concentrate is expelled to the skin surface.

[0072] Blends of different hydrocarbons can be used in the propellant to change the properties of the foam. For example, AP-70 propellant contains more propane to produce a higher pressure propellant bubble, and therefore should produce slightly larger foam bubbles. AP-70 propellant should also cause the foam bubble to expand slightly after coming out of the can and "break faster" than the foam with low pressure AP-48 as the propellant. When a side-by-side comparison of carrier foams inflated with AP-48 or AP-70 propellants was made, the AP-48 propellant foam was more durable in appearance and broke slightly slower, and therefore was preferred. Both AP-48 and AP-70 hydrocarbon blends showed good local foam properties and excellent aesthetics.

[0073] The compositions according to the present invention can be formulated with additional components such as fillers, carriers and excipients commonly found in cosmetic and pharmaceutical topical products. Additional components can be added to the composition, including but not limited to preservatives (e.g., parabens, benzyl alcohol, phenylmercuric salts, chlorocresol), antioxidants, chelating agents, stabilizers, buffers, pH adjusting solutions, skin penetration enhancers, film formers, dyes, pigments, diluents, fillers, fragrances and other excipients to improve stability or aesthetics.

[0074] The low water-soluble active pharmaceutical ingredient can be selected from active substances with a water solubility of less than 60 mg / L. Such active substances include, but are not limited to, ketoconazole, econazole nitrate, ivermectin, clobetasol propionate, calcipotriene, halobetasol propionate, tazarotene, oxymetazoline free base and desonide.

[0075] Table 7. Water solubility data:

[0076] Active pharmaceutical ingredients Water solubility (mg / L) Ketoconazole 0.09 Roflumilast 0.54 Econazole nitrate 1.48* Ivermectin 4 Clobetasol Propionate 4 Calcipotriene 13.5 Halobetasol Propionate 14 Tazarotene 32 Oxymetazoline free base 52* Desonide 59 Azelaic acid 2,140 Minoxidil 2,200 Salicylic acid 2,480 Minocycline Hydrochloride 50,000 Oxymetazoline hydrochloride 145,000 Clindamycin phosphate 250,000 Urea 1,190,000

[0077] *ALOGPS calculated value

[0078] Depending on the condition being treated, in addition to the low water-soluble active pharmaceutical ingredient, the composition according to the present invention may also be formulated with other active agents. Other active agents include, but are not limited to, anthralin (dithranol), azathioprine, tacrolimus, coal tar, methotrexate, methoxsalen, salicylic acid, ammonium lactate, urea, hydroxyurea, 5-fluorouracil, propylthiouracil, 6-thioguanine, sulfasalazine, mycophenolate mofetil, fumaric acid esters, corticosteroids (e.g.,Aclometasone, Amcinonide, Betamethasone, Clobetasol, Clocotolone, Mometasone, Triamcinolone, Fluocinolone, Fluocinonide, Flurandrenolide, Diflorasone, Desonide, Desoximetasone, Dexamethasone, Halcinonide, Halobetasol, Hydrocortisone, Methylprednisolone, Prednicarbate, Prednisone, Corticotropin, Vitamin D analogs Analogues (e.g., calcipotriene, calcitriol), Acitretin, Tazarotene, Cyclosporine, Resorcinol, Colchicine, Adalimumab, Ustekinumab, Infliximab, bronchodialators (e.g., beta-agonists, anticholinergics, theophylline), and antibiotics (e.g., erythromycin, ciprofloxacin, metronidazole). Pharmaceutically active agents with low solubility in water can be encapsulated to control the rate of release from the composition and to protect the active agent from degradation. Encapsulation can also be used to modify skin penetration. Methods for encapsulating active pharmaceutical ingredients are known in the art and include, but are not limited to, encapsulation in liposomes, microparticles, nanoparticles, nanocarriers, nanospheres, microspheres, microcapsules, nanocapsules, nanosponges, and microsponges.

[0079] The foam composition may be administered according to a regimen suitable for the condition being treated, preferably, the foam composition is administered once or more per day, more preferably, the foam composition is administered 1-2 times per day.

[0080] The compositions can be used in veterinary and human medicine for the treatment and prevention of all diseases treatable or preventable by the use of low water-soluble active substances, including but not limited to proliferative, inflammatory and allergic skin diseases, such as soriasis (vulgaris), eczema, atopic dermatitis; parasitic infections; fungal infections of the skin; bacterial or fungal overgrowth; acne; rosacea and red vascular rosacea; and lichen sclerosus.

[0081] The following examples are provided to ensure that one of ordinary skill in the art can make and use the methods and compositions of the present invention. These examples are not intended to limit the scope of what the inventors consider to be the present invention. Other advantages and modifications will be apparent to those skilled in the art.

[0082] Example

[0083] Example 1

[0084] Eight different hydrocarbon propellants, a 47 / 53 weight ratio n-butane / dimethyl ether blend, and the hydrofluorocarbon HFA134a were added to the foam concentrates listed in Table 8 [Formulation 1 or Formulation 2], and the appearance of the spray foam was recorded after gently shaking the can. The target ratio was 5 grams of propellant to 62 grams of foam concentrate. As can be seen from Table 6, the use of n-butane or isobutane alone and the use of a blend of propane and isobutane as propellants produced a runny product that did not meet the appearance requirements of the foam. However, the spray foam produced by the propane / isobutane / n-butane blended propellant was smooth, white and uniform. The foams using these three hydrocarbon propellant blends could initially support their own weight, but were prone to breaking during rubbing. The addition of isopentane to the propane / isobutane / n-butane propellant blend caused the sprayed foam to become unstable and produced a runny product.

[0085] Table 8.

[0086]

[0087] Dimethyl ether is often added to hydrocarbon propellants to increase the solubility of water-insoluble actives in the can, especially when the foam concentrate contains alcohols (ethanol or isopropanol). As seen in Table 6, the addition of dimethyl ether to n-butane results in a product that looks runny when dispensed and does not meet the appearance requirements of the foam.

[0088] HFA-134a (1,1,1,2-tetrafluoroethane) is used for high water-soluble urea and salicylic acid As a propellant in emollient foams, HFA-134a was combined with Formulation 1. The spray product was a lumpy, gel-like mass without air bubbles distributed in the liquid.

[0089] Example 2 Determination of the uniformity of the dispersed contents throughout the canister life

[0090] The appearance of 64 grams of foam concentrate (Formulation 1, containing 0.15% roflumilast) when aerated with 5, 6, 8 or 10 grams of AP-70 propellant was compared. The appearance of the foam sprayed at these four ratios of foam concentrate to propellant was indistinguishable, all being smooth white foam products with small, uniformly sized bubbles.

[0091] Additional analytical testing was completed for Formulation 1 (containing 0.3% Roflumilast) to determine the uniformity of the dispersed Roflumilast content throughout the useful life of the can. Two clinically relevant doses (~1 gram) were dispensed from the beginning of the can (initial priming was performed after the can was shaken by hand approximately 5 times). The amount of foam dispensed was quantified by the difference in weight of the can, and the test results of these two separate foam extractions were averaged to obtain the "beginning average". 15 grams of foam were dispensed and the can was then allowed to return to room temperature. The can was shaken by hand 5-6 times again, and then two clinically relevant doses (~1 gram) were dispensed from the middle of the can. The test results of these two separate foam extractions were averaged to obtain the "middle average". Another 15 grams of foam was dispensed and the can was allowed to return to room temperature. This sampling sequence was repeated to obtain the "end average" data. Table 9 shows the comparative data of the "beginning average", "middle average" and "end average" for the PGX-C batch containing 10 grams of AP-70 propellant and the batch containing 8 grams of AP-70 propellant.

[0092] According to USP <607> Pharmaceutical Foams—Product Quality Tests, uniformity of dispersed contents shall not exceed 10% throughout the usable life of the can. This compendial method instructs to collect appropriate amounts of individually weighed foamed drug products separately, dispensing a certain amount according to the instructions on the scale. The sample size should not exceed the maximum dose recommended for a single use on the product scale. The scale's instructions for use determine whether the can should be shaken before dispensing the foam and the orientation (upright or inverted) when dispensing. The foam fractions corresponding to 1) the beginning of the filled can, 2) the fraction from the middle of the can (within the range of 40%–60% of the scaled can contents), and 3) the fraction corresponding to the can contents with 85% of the scaled contents delivered should be retained. The can should be dispensed at room temperature. If the can cools due to dispensing, the can should be warmed to room temperature before subsequent dispensing. The drug concentration in each of these three fractions is determined using appropriate sample preparation (such as degassing) and analytical methods. All three results are within the product assay range. The maximum difference in the amount of active ingredient measured in the cans was NMT 10.0% (beginning, middle and end).

[0093] As shown in Table 9, the addition of 10 grams of HC propellant destabilizes the O / W emulsion in the can. When the can is shaken, the liquid propellant (specific gravity = 0.54) mixes with the internal oil phase (petrolatum / isopropyl palmitate / cetostearyl alcohol mixture, specific gravity = 0.83) and causes the now swollen emulsion globule to rise from the inverted valve / actuator (creaming of the emulsion). Since the water-insoluble active is disproportionately present around the emulsion oil phase, this process of repeatedly shaking the can and spraying the foam helps to concentrate the active in the can. When the O / W emulsion is unstable to the point where it is not as stable as the oil phase according to USP <607> When the maximum variation limit specified for content uniformity (no more than 10%) throughout the useful life of the canister is exceeded, the aerosol foam drug product is no longer commercially viable. For Formulation 1 with a target fill weight of 64 grams of 0.3% roflumilast, increasing the amount of AP-70 hydrocarbon propellant suddenly and unexpectedly destabilized the foam concentrate emulsion, making the foam drug product no longer acceptable as a marketed drug product.

[0094] Table 9.

[0095]

[0096] Example 3 Effect of increasing the concentration of diethylene glycol monoethyl ether

[0097] The same USP as detailed in Example 2 was used. <607> Pharmaceutical Foams—Product Quality Tests were conducted to determine the uniformity of the dispersed contents throughout the useful life of the can and the effect of increasing concentrations of diethylene glycol monoethyl ether were determined (Table 10).

[0098] Table 10.

[0099]

[0100]

[0101] When the O / W emulsion is unstable according to USP <607> When the maximum variation limit specified for content uniformity (no more than 10%) is exceeded throughout the useful life of the canister, the aerosol foam drug product is no longer commercially viable. For a 0.3% roflumilast foam concentrate with a target fill of 64 grams and an AP-70 hydrocarbon propellant with a target fill of 8 grams, the emulsion in the canister suddenly and unexpectedly became unstable when the DEGEE concentration was increased from 35% to 40% (Table 10). The emulsion of this foam drug product containing 40% DEGEE was not accepted for commercial drug products.

[0102] Table 11.

[0103]

[0104] Example 4

[0105] As detailed in Example 2, two clinically relevant doses (~1 gram) were dispensed from the beginning, middle, and end of the can. The amount of foam dispensed was quantified by the difference in weight of the can, and the measurements of these two separate foam extractions were averaged to yield the beginning mean (B), middle mean (M), or end mean (E) shown in Table 11. After each pair of clinically relevant actuations, approximately 15 grams of foam were dispensed into glass containers, tightly sealed, and stored for optional measurement. These samples were labeled beginning retention (BR), middle retention (MR), and end retention (ER). Six measurements of Formulation 4 from Table 10 (which represent measurements of the entire contents of the can) are shown in Table 12.

[0106] Table 12.

[0107]

[0108] The data presented in Table 12 provide a striking example of how creaming of a foam concentrate emulsion in a can can lead to dramatic changes in the dose level of active substance administered to a patient. It is known from studies of roflumilast emulsion formulations that increasing the amount of DEGEE from 25% to 40% will increase the solubility of roflumilast in the foam concentrate, but increasing the amount of DEGEE above 35% will also destabilize the emulsion. The measurement pattern after full measurement of the can (Table 12) indicates that the active substance is moving to the portion of the emulsion containing roflumilast that remains in the can during the start-up. The data in Table 12 can be understood by performing the measurement steps. The entire can of product was shaken and the first gram of sample was dispensed, and the measurement value was 96.4%. The can was shaken again, and about 15 grams of foam could be dispensed into the jar in one start-up - the roflumilast-rich propellant-expanded globules of the unstable emulsion phase separated (creamed) and moved away from the valve of the inverted can. Creaming of the emulsion carries a disproportionate amount of Roflumilast to the interface between the emulsion and the liquid propellant, which ensures that the measured value of the "starting retention" is very small, only 69.4%. The can was allowed to return to room temperature, shaken, and after a short actuation, a 1 gram intermediate sample was taken and measured to be 99.0% of the nominal amount. Again, due to the instability of the emulsion, Roflumilast escaped from being dispensed from the can during the long actuation during the dispensing of the "intermediate retention" (72.2% of the nominal amount). Since about two-thirds of the three-phase drug aerosol has been dispensed at low potency, the 1 gram final actuation has the highest measured value (131.3% of the nominal amount). The last long actuation that produced the "end retention" measured value maintained the trend of having a lower Roflumilast measured value (111.0% of the nominal amount) compared to the final sample (131.3% of the nominal amount). Depending on the length of time the can is inverted after shaking, the physically unstable emulsion foam product can deliver 69% of the labeled dose or 131% of the labeled dose. Formulation 4 is not a commercially viable pharmaceutical aerosol foam product.

[0109] Example 5 Ratios of hydrocarbon blends

[0110] The ARQ-154 foam formulations (64 grams of concentrate) shown in Table 2 were compared for aesthetics when inflated with 8 grams of AP-48 or AP-70 propellants. The AP-48 propellant is a blend of propane:isobutane:n-butane of 31:23:46, while the AP-70 propellant is a blend of propane:isobutane:n-butane of 55:15:30. While both foams were found to be fully acceptable, approximately two-thirds of the product testers preferred the firmer appearance and slightly slower break of the AP-48 propellant foam. The other third of the testers had no preference or a slight preference for the faster-breaking AP-70 foam. In conclusion, both the AP-48 and AP-70 hydrocarbon blends exhibited good localized foam properties and excellent aesthetics. By adjusting the ratio of propane to the isobutane / n-butane mixture, any pressure between 48 and 70 psig can be achieved. From an aesthetic point of view, hydrocarbon propellant blends of propane / isobutane / n-butane in any ratio that produces a pressure of about 48-70 psig at 70°F have been shown to be acceptable.

[0111] Example 6. Formulations containing various low water-soluble APIs

[0112] Table 13

[0113]

[0114] Table 14

[0115]

[0116] Table 15

[0117]

[0118]

[0119] Table 16

[0120]

[0121] Table 17

[0122]

[0123]

[0124] Example 7 Tank Lining Compatibility Test

[0125] Since the introduction of the hexane extraction step significantly reduced the variability of the assay results, samples with commercially available can liners were filled with 0.3% foam concentrate and aerated with AP-70 propellant. Three different sizes of cans were compared with glass compatible bottles. The current 60 gram cans of Roflumilast foam were compared with larger Trivium cans (PPG-2845 and PPG-8900), which were 53 mm x 235 mm cans filled with 275.2 grams of concentrate (equivalent to 64 grams of concentrate for the 60 gram can) and 34.4 grams of AP-70 propellant (equivalent to 8 grams of propellant for the 60 gram can). Smaller 10 gram sample cans of Roflumilast foam were filled with 12.0 grams of concentrate and 2.3 grams of AP-70 propellant. The bulk concentrate was packaged and propellant was added. The cans were stored inverted and upright at ambient conditions. The bottles were aerated and shipped on the same day, but stored upright and horizontally. Table 18 shows the measurement results of roflumilast, methylparaben (MP), and propylparaben (PP).

[0126] Table 18. Results of tank lining compatibility study after ambient storage for more than one month.

[0127]

[0128]

[0129] The variability of the results and the lower than expected values ​​for the glass bottle samples make it difficult to accurately determine the losses caused by the tank lining. However, the trend of the data indicates that the epoxy phenolic resin liner is the best in maintaining close to the target roflumilast value, the MPE and BPA are similar but slightly inferior to the epoxy phenolic resin liner, and the current PAM liner is the least compatible liner with the roflumilast foam product. From the data in Table 18, it can be seen that the epoxy phenolic resin liner may be incompatible with parabens, especially propylparaben. If incompatibility between these preservatives and the epoxy phenolic resin tank liner is confirmed, it may be necessary to overdose roflumilast to compensate for the slight loss of roflumilast due to the use of the PAM tank liner in the primary container of the roflumilast foam.

[0130] Example 8 Roflumilast foam final formulation experiment

[0131] In order to select the final roflumilast formulation for the manufacture of these three major stability batches, stability tests were performed on four packaging / propellant combination matrices. The four configurations are: 1) current PAM lined cans, aerated with AP-70 propellant (Phase 2 IP), 2) current PAM lined cans, aerated with AP-48 propellant, 3) epoxy phenolic resin lined cans, aerated with AP-70 propellant, and 4) epoxy phenolic resin cans, aerated with AP-48 propellant. The product concentrate has the composition shown in Table 2 and IPP is added to the active substance phase during processing. The target fill weight of the product concentrate is 64.0 grams and the target fill weight of the propellant is 8.0 grams. Forty (40) cans are filled for each of the four configurations, aerated and stability tested. Three (3) cans will be taken out from each configuration at a time and tested for assays, impurities and preservatives.

[0132] Example 9 Storage Stability

[0133] The following formulations were prepared and mixed with propellant AP-48 or AP-70 to determine if a stable foam would form after storage for more than 30 days at ambient conditions.

[0134] Table 19

[0135]

[0136]

[0137] Example 10 Evaluation of Foam Quality

[0138] Foams were prepared and evaluated using foam quality and foam expansion techniques. Five foam formulations containing active pharmaceutical ingredients with low solubility in water were prepared to determine whether a suitable foam product was produced. The APIs included ivermectin, clobetasol propionate, oxymetazoline free base, ketoconazole, and econazole nitrate. The product concentrate containing the API was mixed with NIP-70 propellant at a ratio of 88.9% product concentrate to 11.1% propellant. All five formulations produced foams as shown in FIG. Figure 2-6 Foam product shown. Foam quality was assessed visually and using foam density and foam expansion techniques.

[0139] Prepare the aerosol can assembly according to the table below.

[0140] Table 20

[0141] Aerosol components used describe 35mm x 125mm can AER PAM 8460N Valve stem S90,018,(630EQL)Spline type Stem gasket S90, BUNA, B1785 non-food grade spring S90,STEM,020,Stainless steel Valve body S90, Inverted Housing w / Tail Piece 4 with Slots Mounting cup Aluminum spherical cup, Epon T / B Dip tube STD,LLDPE,0.122Nat 5K FT

[0142] The sample variable tolerances are as follows.

[0143] Table 21

[0144] variable Minimum Target value Maximum Foam Concentrate Fill Weight 60.8g 64.0g 67.2g Propellant Fill Weight 7.6g 8.0g 8.4g Crimp height 0.208” 0.210” 0.212” Crimp diameter 1.065” 1.07” 1.075”

[0145] Embodiment 11

[0146] Four formulations were tested for each of five different low water-soluble active substances: ivermectin, clobetasol propionate, oxymetazoline, ketoconazole, and econazole nitrate.

[0147] Samples were prepared for each variable. Each can was filled with 64 g of product concentrate containing the API and then crimped. The can was then pressurized with 8 g of NIP-70 propellant. The propellant was manually filled using a burette system, followed by gravimetric analysis of individual samples. A range of + / - 5% from the target weight was considered acceptable. No sample deviated from the target value by more than 3%. The finished aerosol product utilized 75% of the specified can edge fill capacity. The finished can was immersed in a 55°C water bath for 10 minutes to test it for leaks. No leaks were detected during a visual inspection of the immersed can. The finished can was shaken by hand for no more than 10 seconds and left to stand for at least 2 days to ensure that the propellant and product concentrate were completely mixed.

[0148] The samples were studied using visual analysis to determine if foam was present after dispensing. Foam was defined as the visual presence of multiple bubbles sharing at least one liquid film wall that could break when disturbed by an external force. The foam was visually analyzed immediately after dispensing and again five minutes after dispensing. Formulations 5-8, 10, 12-21, 23, and 24 were found to produce acceptable foam immediately after dispensing and at 5 minutes after dispensing. Acceptable foam was a smooth white or off-white foam with uniform bubbles and capable of supporting its own weight. The half-life of the foam was more than 60 seconds. The resulting foam was as follows: Figure 2-6 As shown. All tested formulations of all five APIs produced foam. A wide range of foam structures was observed for the different formulations, showing the range of foams that can be produced using the APIs tested. The foam structure can be optimized for specific indications.

[0149] Preparation No. appearance As shown in Fig. Preparation 5 Ketoconazole Acceptable expanding foam 2 Preparation 6 Ketoconazole Acceptable thick foam 2 Preparation 7 Ketoconazole Acceptable expanding foam 2 Preparation 8 Ketoconazole Acceptable rigid foam 2 Preparation 9 Econazole nitrate Unacceptable splash foam 3 Preparation 10 Econazole nitrate Acceptable thick foam 3 Preparation 11 Econazole nitrate Unacceptable splash foam 3 Preparation 12 Econazole nitrate Acceptable thick foam 3 Preparation 13 Ivermectin Acceptable expanding foam 4 Preparation 14 Ivermectin Acceptable expanding foam 4 Preparation 15 Ivermectin Acceptable expanding foam 4 Preparation 16 Ivermectin Acceptable fast-bursting foam 4 Preparation 17 Clobetasol propionate Acceptable fast-bursting foam 5 Preparation 18 Clobetasol propionate Acceptable fast-bursting foam 5 Preparation 19 Clobetasol propionate Acceptable fast-bursting foam 5 Preparation 20 Clobetasol propionate Acceptable fast-bursting foam 5 Preparation 21 Oxymetazoline free base Acceptable thick foam 6 Preparation 22 Oxymetazoline free base Unacceptable splash foam 6 Preparation 23 Oxymetazoline free base Acceptable rigid foam 6 Preparation 24 Oxymetazoline free base Acceptable rigid foam 6

Claims

1. An aerosol foam comprising an active pharmaceutical ingredient having a water solubility of less than 60 mg / l, cetearyl alcohol, dicetyl phosphate and ceteareth-10 phosphate in an oil-in-water emulsion; and a propane / isobutane / butane propellant blend, wherein the active pharmaceutical ingredient having a water solubility of less than 60 mg / l is not roflumilast.

2. The aerosol foam according to claim 1, wherein the viscosity of the oil-in-water emulsion is 4,000-11,000 cP.

3. The aerosol foam of claim 1, wherein the ratio of the propellant to the oil-in-water emulsion is about 1:8 to 1:

6.

4. The aerosol foam of claim 1, wherein the aerosol foam is ejected from a container but collapses after being applied to the skin of a subject.

5. The aerosol foam according to claim 1, wherein the active pharmaceutical ingredient is selected from the group consisting of ketoconazole, econazole nitrate, ivermectin, clobetasol propionate, calcipotriene, halobetasol propionate, tazarotene, oxymetazoline free base and desonide.

6. The aerosol foam according to claim 1, further comprising at least one component selected from the group consisting of hexylene glycol and diethylene glycol monoethyl ether.

7. The aerosol foam according to claim 6, wherein the amount of diethylene glycol monoethyl ether is 25% w / w to 35% w / w.

8. The aerosol foam according to claim 6, further comprising at least one additional component selected from the group consisting of solvents, humectants, surfactants or emulsifiers, polymers or thickeners, preservatives, antioxidants, chelating agents, stabilizers, buffers, pH adjusting solutions, skin penetration enhancers, film formers, dyes, pigments and fragrances.

9. The aerosol foam according to claim 6, further comprising an additional active agent selected from the group consisting of anthralin, azathioprine, tacrolimus, coal tar, methotrexate, methoxsalen, salicylic acid, ammonium lactate, urea, hydroxyurea, 5-fluorouracil, propylthiouracil, 6-thioguanine, sulfasalazine, mycophenolate mofetil, fumarate esters, corticosteroids, corticotropin, vitamin D analogs, acitretin, tazarotene, cyclosporine, resorcinol, colchicine, adalimumab, ustekinumab, infliximab, bronchodilators and antibiotics.

10. The aerosol foam of claim 1, wherein the cetearyl alcohol, dicetyl phosphate and ceteareth-10 phosphate are in the emulsifier blend in an amount of 2 to 4% by weight of the total composition.

11. An aerosol foam according to claim 10, wherein the amount of the emulsifier blend is 2% by weight of the total composition.

12. The aerosol foam according to claim 1, further comprising water in an amount of 55 to 70 wt% of the total composition.

13. The method of claim 1, wherein the amount of the active pharmaceutical ingredient is 0.05 to 2 weight % of the total composition.

14. The aerosol foam of claim 1, wherein the aerosol foam comprises the active pharmaceutical ingredient, white petrolatum, isopropyl palmitate, cetearyl alcohol, dicetyl phosphate, ceteareth-10 phosphate, hexylene glycol, diethylene glycol monoethyl ether, methylparaben, propylparaben, purified water, and a propane / isobutane / butane propellant blend.

15. A method of treating a patient suffering from an inflammatory skin condition comprising topically applying to a patient in need thereof an aerosol foam comprising an active pharmaceutical ingredient having a water solubility of less than 60 mg / l, cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphate in an oil-in-water emulsion; and a propane / isobutane / butane propellant blend, wherein the active pharmaceutical ingredient having a water solubility of less than 60 mg / l is not roflumilast.

16. The method of claim 14, wherein the aerosol foam further comprises hexylene glycol and / or diethylene glycol monoethyl ether.

17. The method of claim 16, wherein the amount of diethylene glycol monoethyl ether is 25% w / w to 35% w / w.

18. The method of claim 14, wherein the composition is administered 1-2 times per day.

19. The method of claim 15, wherein the patient suffers from a proliferative, inflammatory and / or allergic skin disease.

20. The method of claim 19, wherein the proliferative, inflammatory and allergic skin disease is selected from the group consisting of psoriasis (vulgaris), eczema, acne, lichen simplex, lichen sclerosus, prurigo nodularis, sunburn, pruritus, alopecia areata, hypertrophic scars, discoid lupus erythematosus and pyoderma.

21. The method of claim 19, wherein the patient suffers from an inflammatory skin disease.

22. The method of claim 21, wherein the patient suffers from atopic dermatitis.

23. The method of claim 15, wherein the aerosol foam is free of hexylene glycol.

24. A method for dissolving an active pharmaceutical ingredient having a water solubility of less than 60 mg / l in an aerosol foam, comprising: combining an active pharmaceutical ingredient having a water solubility of less than 60 mg / l, cetearyl alcohol, dicetyl phosphate and ceteareth-10 phosphate in an oil-in-water emulsion, and combining the oil-in-water emulsion with a propane / isobutane / butane propellant blend to produce an aerosol foam, The active pharmaceutical ingredient having a water solubility of less than 60 mg / l is not roflumilast.

25. An aerosol foam comprising an active pharmaceutical ingredient having a water solubility of less than 60 mg / l, cetearyl alcohol, dicetyl phosphate, ceteareth-10 phosphate and diethylene glycol monoethyl ether in an oil-in-water emulsion, and a propane / isobutane / butane propellant blend, wherein the oil-in-water emulsion has a viscosity of 4,000-11,000 cP, wherein the foam does not contain hexylene glycol, wherein the amount of diethylene glycol monoethyl ether is 25% w / w to 35% w / w, wherein the aerosol foam is ejected from a container but collapses after application to a subject's skin, and wherein the foam half-life of the aerosol foam is greater than 60 seconds.

Citation Information

Patent Citations

  • Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors

    US5712298A

Cited By

  • Compound ketoconazole foaming agent composition as well as preparation method and application thereof

    CN122376535A